728 Conclusions The unabated rise in the global prevalence of neurodegenerative diseases, 751 coupled with the suboptimal therapeutic outcomes of current FDA-approved drugs, emphasize the need for an alternative strategy to discover effective therapeutic targets

Common causes of lymphadenopathy that may coincidentally occur during GLP-1 treatment include: Viral or bacterial infections : Upper respiratory tract infections, pharyngitis, dental infections, and other common illnesses frequently cause reactive lymph node enlargement, particularly in the neck, jaw, or armpit regions Localised skin infections or inflammation : Cellulitis, abscesses, or infected wounds near lymph node chains can trigger regional lymphadenopathy Systemic infections : Conditions such as infectious mononucleosis (glandular fever), cytomegalovirus, or toxoplasmosis may present with generalised lymph node swelling Immune-mediated conditions : Rheumatoid arthritis, lupus, and other autoimmune disorders can cause lymphadenopathy Malignancy : Lymphomas, leukaemias, or metastatic cancer may present with persistent or progressive lymph node enlargement Recent vaccination : Transient lymph node enlargement in the region draining the vaccination site is a common benign reaction It is worth noting that injection site reactions are recognised side effects of GLP-1 medications, typically manifesting as localised redness, swelling, or discomfort at the injection site rather than distant lymph node enlargement

Ipamorelin is not FDA approved for general wellness use
Some patients find relief using over-the-counter saliva substitutes or oral moisturizing gels, which are available at most pharmacies and can be particularly helpful at night when xerostomia symptoms often worsen
Unlike GLP-1 drugs, it works within the bodys natural hormonal pathways, making it a low-risk, accessible option for those looking to optimize their diet